A Link Between Air Pollution and Dementia Risk Is Supplied by New Data.

Published Date: 23 Apr 2023

According to the study, prolonged exposure to nitrogen dioxide, particulate matter PM2.5, and nitrogen oxide may raise the risk of dementia.

Read Full News

Latest News

The HCPFive: Top News for Healthcare Providers from the Week of 11/1

The HCPFive: Top News for Healthcare Providers from the Week of 11/1

Q&A: Discussing 2027 GOLD Report Updates in COPD, With David Singh, MD

Q&A: Discussing 2027 GOLD Report Updates in COPD, With David Singh, MD

AI Not Yet Ready for COPD Prognosis, With Jean Bourbeau, MD Jean Bourbeau, MD

AI models have not outperformed existing clinical scores for COPD prognosis, but home monitoring may help track disease activity, Bourbeau said.

Breath-Hold Does Not Improve Robotic Bronchoscopy Yield: STABLE Trial Roshen Mathew, MD, DAABIP

Among 117 patients, breath-hold ventilation did not improve strict diagnostic yield vs conventional (86.8% vs 92.2%) in robotic bronchoscopy.

AD109 Cuts AHI by 59.6% in Postmenopausal Women With OSA Reena Mehra, MD

In a post hoc analysis of 2 phase 3 trials, AD109 reduced hypoxic burden by 69.8% vs 20.0% with placebo in postmenopausal women with OSA.

Q&A: Why IL-33 Matters for Mucus Plugs, Inflammation in COPD

Q&A: Why IL-33 Matters for Mucus Plugs, Inflammation in COPD

Todays Updates

Closing the COVID-19 Prevention Gap This Flu Season, With Juanita Mora, MD

Closing the COVID-19 Prevention Gap This Flu Season, With Juanita Mora, MD

Examining High-Dose Influenza Vaccination and Alzheimer Disease Risk Louie Pasculli

Darren Gitelman, MD, senior medical director of the Advocate Memory Center in Park Ridge, discusses findings linking high-dose influenza vaccination to lower Alzheimer disease risk, study limitations, and potential implications for future dementia prevention research.

FDA Investigates Confirmed Insertional Oncogenesis With Spinal Muscular Atrophy Gene Therapy Isabella Ciccone, MPH

Postmarketing reports of product-related insertional oncogenesis involving GLI1 have prompted an FDA investigation into malignancy risk with SMA gene therapy, onasemnogene abeparvovec.

Todays Updates

Closing the COVID-19 Prevention Gap This Flu Season, With Juanita Mora, MD

Closing the COVID-19 Prevention Gap This Flu Season, With Juanita Mora, MD

Examining High-Dose Influenza Vaccination and Alzheimer Disease Risk Louie Pasculli

Darren Gitelman, MD, senior medical director of the Advocate Memory Center in Park Ridge, discusses findings linking high-dose influenza vaccination to lower Alzheimer disease risk, study limitations, and potential implications for future dementia prevention research.

FDA Investigates Confirmed Insertional Oncogenesis With Spinal Muscular Atrophy Gene Therapy Isabella Ciccone, MPH

Postmarketing reports of product-related insertional oncogenesis involving GLI1 have prompted an FDA investigation into malignancy risk with SMA gene therapy, onasemnogene abeparvovec.

Latest News

The HCPFive: Top News for Healthcare Providers from the Week of 11/1

Q&A: Discussing 2027 GOLD Report Updates in COPD, With David Singh, MD

AI models have not outperformed existing clinical scores for COPD prognosis, but home monitoring may help track disease activity, Bourbeau said.

Among 117 patients, breath-hold ventilation did not improve strict diagnostic yield vs conventional (86.8% vs 92.2%) in robotic bronchoscopy.

In a post hoc analysis of 2 phase 3 trials, AD109 reduced hypoxic burden by 69.8% vs 20.0% with placebo in postmenopausal women with OSA.

Q&A: Why IL-33 Matters for Mucus Plugs, Inflammation in COPD

News All Time

Inhaled Treprostinil Reduces Recurrent IPF Events, With Steven Nathan, MD Steven D. Nathan, MD, FCCP

A TETON-2 post hoc analysis at CHEST 2026 found 126 progression events with inhaled treprostinil vs 161 with placebo across 52 weeks.

AI Could Help Find Undiagnosed COPD on Lung Cancer Screening CT Jean Bourbeau, MD

Jean Bourbeau, MD, says AI analysis of CT scans is not ready for routine use but could reshape early COPD diagnosis as GOLD expands its AI guidance.

Voceryq Gains FDA Accelerated Approval for Recurrent Respiratory Papillomatosis

Voceryq Gains FDA Accelerated Approval for Recurrent Respiratory Papillomatosis

STABLE Trial: Breath-Hold Does Not Improve Robotic Bronchoscopy Yield Roshen Mathew, MD, DAABIP

Roshen Mathew, MD, DAABIP, discusses STABLE, in which diagnostic yield was 86.8% with breath-hold vs 92.2% with conventional ventilation.

Depemokimab Year 1 Remission Linked to Better Year 2 Asthma Outcomes Michael Wechsler, MD, MSc

Michael Wechsler, MD, reports 59% of patients in clinical remission with twice-yearly depemokimab at year 1 maintained it at year 2 in SWIFT/AGILE.

Experts Discuss PAH Treatment Selection and Access

Experts Discuss PAH Treatment Selection and Access

HCPLive Five at CHEST 2026

HCPLive Five at CHEST 2026

Tozorakimab Improves Daily Respiratory Symptoms in COPD: OBERON, TITANIA Frank C. Sciurba, MD

Frank Sciurba, MD, reports tozorakimab improved E-RS:COPD scores vs placebo at week 52 in OBERON and TITANIA, including breathlessness and chest symptoms.

Earlier PH Screening in ILD: PHINDER Data, With Parth Rali, MD

Earlier PH Screening in ILD: PHINDER Data, With Parth Rali, MD

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

Recommended News For You

A person's susceptibility to papillary thyroid cancer may be determined by variations in telomere lengthening genes.

More Data Back Teclistamab for Autoimmune Disease

Induction Immunotherapy Has Durable Survival Benefit in LACC

Global inequalities found in cancer research funding

Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer

Is Lenalidomide Resistance in Myeloma Reversible with JAK Inhibition?

No Cellphone, Brain Cancer Link; Testosterone Paradox; Breast Density and Cancer

Recommended Articles For You

Community-Based Cancer Prevention Through Environmental Risk Mapping 

Electronic Blood-Product Inventory Networks: Clinical Governance, Interoperability, and Patient-Safety Implications 

Bone Marrow Microenvironment Remodeling in Hematologic Disorders 

Targeting the Tumor Microenvironment: Next-Generation Strategies for Immuno-Oncology Success 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study: One-week breast cancer radiotherapy proven as safe and effective as standard three-week treatment

2.

Junk Food & Prostate Cancer; 'Office' Star's Stage IV Diagnosis; New Cancer Cluster?

3.

Booze and Pancreatic Cancer Risk; From 'Hospice' to 'Hope'; Gen Z-ers Skip Screening

4.

How a new light-based cancer treatment could destroy tumors without harming healthy cells—using LEDs

5.

Promising for Monitoring and Diagnosis of AD is the finger-prick test.

1.

Comprehensive Techniques in Hematology in Clinical Decision-Making

2.

Transplant Oncology and Anti-Cancer Immunosuppressants: The Evolution of a Paradigm in Cancer Care

3.

Undersanding Alemtuzumab: What You Need To Know About This Multiple Sclerosis Medication

4.

Risk Assessment of Iron Overload in Repeated Transfusion

5.

Epigenetic Signatures for Multi-Cancer Screening

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV

2.

Predicting Delayed Hemolytic Transfusion Reactions Through Donor-Recipient Antigen Exposure Modeling

3.

The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma

4.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V

5.

Current Scenario of Cancer- The Incidence of Cancer in Men

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot